Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis

Br J Haematol. 2022 Jul;198(2):401-404. doi: 10.1111/bjh.18231. Epub 2022 May 11.
No abstract available

Keywords: Hodgkin lymphoma; anti-programmed death 1; checkpoint inhibition; real-world; relapsed/refractory.

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hodgkin Disease* / drug therapy
  • Humans
  • Nivolumab

Substances

  • Nivolumab